NCT07573488 Sleep, Stress and Migraine - an Observational and Training Study
| NCT ID | NCT07573488 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Susanne Wegener |
| Condition | Migraine |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-05-18 |
| Primary Completion | 2027-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-05-18 with a primary completion date of 2027-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The MiSleepS study investigates how sleep disturbances and stress are linked to migraine attacks. Participants wear a device called a WHOOP band, which tracks sleep and body signals, and answer brief daily questions via a smartphone app about their sleep, stress levels, and migraine symptoms. The goal is to identify personal patterns that may contribute to migraine. Based on these insights, participants receive individualized recommendations to improve their sleep and daily routines - aiming to reduce migraine attacks in the long term without medication. The study is conducted at the University Hospital Zurich and is aimed at adults with episodic migraine.
Eligibility Criteria
Inclusion Criteria: * Adults aged between 18 and 65 years * Diagnosis of episodic migraine according to The International Classification of Headache Disorders (ICHD-3) criteria confirmed by our headache specialists * 4 to 14 headache days per month (mean value based on the 3 months prior to study enrollment) * Ability to give informed consent and to adhere to the study protocol * Sufficient German language comprehension to follow the study procedures and answer all questions related to the study outcomes * Stable migraine medication regimen for the past 3 months and throughout the study period Exclusion Criteria: * Diagnosis of sleep disorders that could interfere with the sleep intervention, such as obstructive sleep apnea with an apnea-hypopnea index (AHI) \> 15, Restless Legs Syndrome, frequent (i.e. weekly) Non-rapid eye movement (NREM) sleep parasomnia, REM Behavior Disorder (RBD) * Current diagnosis of a psychiatric disorder that is inadequately treated or therapy-resistant and may interfere with study participation or adherence to study procedures (this includes, but is not limited to: schizophrenia, schizoaffective disorder, bipolar disorder (type I), post-traumatic stress disorder with active symptoms, or major depressive disorder with ongoing functional impairment despite treatment). Diagnosis must be confirmed by clinical history or treating physician. * Regular use of benzodiazepines and other central nervous system (CNS)-depressant substances (self-reported) * Concomitant steroid medication (self-reported) * Known or suspected alcohol, drug or medication abuse (i.e. \> 0.5 l wine or 1 l beer per day) * Inability to follow the procedures of the study (e.g., due to language problems, cognitive deficits, instable home situation) * Concurrent participation in another study involving drug and behavioral interventions within 3 months prior to and during the present study, as well as participation in an ongoing study with data collection through SEMA3 * Planned medical intervention of substantial relevance requiring hospitalization for more than 24 hours (e.g. surgery) during intervention (routine assessments, e.g. check-ups will be allowed) * Shift work with working during the night * Travelling more than 2 time zones in the last month before the observation or intervention periods or during the study * Persons who are pregnant or breastfeeding
Contact & Investigator
Susanne Wegener
PRINCIPAL INVESTIGATOR
University Hospital Zurich, Department of Neurology
Frequently Asked Questions
Who can join the NCT07573488 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Migraine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07573488 currently recruiting?
Yes, NCT07573488 is actively recruiting participants. Contact the research team at susanne.wegener@usz.ch for enrollment information.
Where is the NCT07573488 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT07573488 clinical trial?
NCT07573488 is sponsored by Susanne Wegener. The principal investigator is Susanne Wegener at University Hospital Zurich, Department of Neurology. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.